Analysis of progesterone in unextracted serum: a method using danazol [17 alpha-pregn-4-en-20-yno(2, 3-d) isoxazol-17-ol] a blocker of steroid binding to proteins

Effects on reproduction of estrous cycle variations, rectal temperatures and liveweights in mated Brahman cross heifers

Estrous cycle variations and the association of rectal temperature with reproductive measurements and liveweight were examined in 25-month-old 1/2 and 3/4 Brahman heifers (n = 88). The mean cycle length was longer in the 1/2 Brahmari (24.3 days) than in the 3 4 Brahman heifers (21.3 days) due to the length of estrus-metestrus, but the overall difference was not statistically significant. Cycle length was not influenced by cycle number or liveweight. Cycles were classified into 6 types: normal, short, long, anovulatory and those involving embryonic mortality and prolonged diestrus. Only 33.6% of 1/2 Brahman cycles and 36.1% of 3/4 Brahman cycles were of normal duration (18 to 24 days), and 13.3% of 1/2 Brahman and 11.6% of 3/4 Brahman cycles were classified as embryonic mortality cycles. On an individual animal basis, 25.0% and 31.8% of 3 4 Brahman heifers, respectively, had cycles in which embryonic mortality was suspected. Heifers that became pregnant were significantly (P < 0.01) heavier throughout mating and had significantly (P < 0.05) lower mean rectal temperatures. Heifers in which embryonic mortality had occurred were lighter and had significantly (P < 0.01) higher rectal temperatures than heifers in which embryonic mortality had not occurred. Correlations between rectal temperature and ambient temperature were nonsignificant after eliminating the effect of genotype, but rectal temperature was significantly (P < 0.01) negatively correlated with liveweight.

Decreased pulsatile LH secretion in heifers superovulated with eCG or FSH

This study was designed to test the hypothesis that treatment with super-ovulatory drugs suppresses endogenous pulsatile LH secretion. Heifers (n=5/group) were superovulated with eCG (2500 IU) or FSH (equivalent to 400 mg NIH-FSH-P1), starting on Day 10 of the estrous cycle, and were injected with prostaglandin F(2alpha) on Day 12 to induce luteolysis. Control cows were injected only with prostaglandin. Frequent blood samples were taken during luteolysis (6 to 14 h after PG administration) for assay of plasma LH, estradiol, progesterone, testosterone and androstenedione. The LH pulse frequency in eCG-treated cows was significantly lower than that in control cows (2.4 +/- 0.4 & 6.4 +/- 0.4 pulses/8 h, respectively; P<0.05), and plasma progesterone (3.4 +/- 0.4 vs 1.8 +/- 0.1 ng/ml, for treated and control heifers, respectively; P<0.05) and estradiol concentrations (25.9 +/- 4.3 & 4.3 +/- 0.4 pg/ml, for treated and control heifers, respectively; P<0.05) were higher compared with those of the controls. No LH pulses were detected in FSH-treated cows, and mean LH concentrations were significantly lower than those in the controls (0.3 +/- 0.1 & 0.8 +/- 0.1, respectively; P<0.05). This suppression of LH was associated with an increase in estradiol (9.5 +/- 1.4 pg/ml; P<0.05 compared with controls) but not in progesterone concentrations (2.1 +/- 0.2 ng/ml; P>0.05 compared to controls). Both superovulatory protocols increased the ovulation rate (21.6 +/- 3.9 and 23.0 +/- 4.2, for eCG and FSH groups, respectively; P>0.05). These data demonstrate that super-ovulatory treatments decrease LH pulse frequency during the follicular phase of the treatment cycle. This could be explained by increased steroid secretion in the eCG-treated heifers but not in FSH-treated animals.

Perspectives for on-site monitoring of progesterone

The steroid hormone progesterone is the primary biomarker of the reproductive status of female mammals. Current techniques of monitoring progesterone are based predominantly on (enzyme) immunoassays, but these are too expensive to be affordable in daily screening programmes because of their associated labour costs and the need for laboratory facilities and/or equipment. Here, we discuss existing methods as well as new perspectives for (automated) application at point of care/need, e.g. the milking parlour. These make it apparent that a low-cost, fully automated progesterone assay system to monitor the reproductive status is far from being realised at present. Timely ovulation prediction techniques for artificial insemination and reproductive cycling are thus urgently needed, and promising perspectives will be highlighted.

Endometriosis of the urinary tract

Genitourinary endometriosis is a rare manifestation of a common disease. Ectopic endometrial tissue may extrinsically involve or intrinsically invade the bladder or ureter, and, less commonly, the urethra or kidney. Bladder involvement usually presents with irritative symptoms, whereas ureteral disease may present with asymptomatic renal failure. Therefore, a high index of suspicion is necessary, and genitourinary endometriosis should be considered in all symptomatic women with a history of cesarean delivery of other gynecologic surgery. In women beyond reproductive age, definitive surgical treatment is preferred, with removal of the ectopic tissue, relief of obstruction, and castration with or without hysterectomy. In those who desire future fertility, conservative surgery and/or hormonal therapy is often recommended.

Effects of 17beta-oestradiol or oestrous stage-specific cow serum on the ability of bovine oviductal epithelial cell monolayers to prolong the viability of bull spermatozoa

The effect of 17beta-oestradiol and oestrous stage-specific cow serum on bovine oviductal epithelial cell monolayers to extend the viability of co-cultured bull spermatozoa was examined. Monolayers of cells from ampullary and isthmic segments were pre-treated with medium containing either oestrous cow serum, luteal-phase cow serum, 1 microg/ml 17beta-oestradiol + foetal bovine serum or foetal bovine serum alone (control) before the addition of motile frozen/thawed spermatozoa. Motility was visually assessed throughout a 48 h co-incubation period, while fertilising ability of spermatozoa was evaluated by adding in vitro matured bovine oocytes. Pre-treatment with 17beta-oestradiol or oestrous cow serum resulted in a higher percentage of motile spermatozoa after 18 h in isthmic and after 36 h in ampullary cultures compared with the control, but pre-treatment did not affect fertilisation rates. Only at 42 h in ampullary cultures was motility higher in luteal serum pre-treated cultures compared to the control. Motility was also assessed in medium conditioned by pre-treated monolayers. Pre-treatment with 17beta-oestradiol enhanced the ability of conditioned medium to prolong motility and medium conditioned with oestrous cow serum was superior to medium conditioned by luteal-phase serum at maintaining motility. In conclusion, the ability of oviductal epithelium to prolong the motility of spermatozoa is enhanced by 17beta-oestradiol.

Effects of short-term treatment with progesterone superimposed on 11 or 17 days of norgestomet treatment on the interval to oestrus and fertility in Bos indicus heifers

The aims of this study were to determine: (1) if short-term treatment of Bos indicus heifers with progesterone (P4) while implanted with a s.c. norgestomet implant for 17 days would influence the time interval to oestrus and increase fertility of the synchronised oestrus, and (2) whether the response to treatment with P4 would differ between heifers treated with a norgestomet implant for 17 vs. 11 days when short-term treatment with P4 is applied 3 days prior to implant removal. B. indicus heifers at two separate sites (A and B) were allocated to three groups at each site. Heifers in two groups (NG and NGP4 groups) were given a single s.c. norgestomet implant on the first day of treatment (day 0) while heifers in a third group (NGP4PG group) were implanted on day 6. A single P4 releasing Controlled Internal Drug Release device (CIDR) was inserted on day 14 in heifers in the NGP4 and NGP4PG groups and was removed 23.5 +/- 0.07 h later (day 15). Heifers in the NGP4PG group were administered an analogue of prostaglandin F2 alpha (PGF2 alpha) at the time of CIDR removal to regress corpora lutea. Implants were removed from all heifers on the same day (day 17) and a 400 IU of equine chorionic gonadotrophin (ECG) was administered s.c. Animals were artificially inseminated 11.1 +/- 0.17 h after detection of oestrus, using frozen semen from one bull at site A and one of five bulls at site B. Inseminations were carried out by one of two technicians. Treatment with P4 delayed oestrus and reduced the synchrony of oestrus at site A (hours to oestrus +/- SD: NG group, 39.0 +/- 13.7; NGP4 group, 66.3 +/- 24.4; NGP4PG group, 58.9 +/- 20.5 h; P < 0.05) but not at site B (41.4 +/- 15.2, 42.5 +/- 10.1, 45.4 +/- 10.3 h; P > 0.05). Pregnancy rates 6 weeks after insemination were found to be significantly associated with bull (P < 0.001), treatment group (P = 0.013) and insemination technician (P = 0.033). Pregnancy rates were greater in the heifers in the NGP4 group than heifers in the NG group [50.3% (78/155) vs. 36.4% (60/165); odds ratio = 1.83, 95% CI = 1.14 to 2.96] and similar between heifers in the NGP4 and NGP4PG groups [50.3% (78/155) vs. 51.1% (63/117); odds ratio = 1.06, 95% CI = 0.67 to 1.69]. It was concluded that acute treatment with P4 can improve pregnancy rates in B. indicus heifers treated for 17 days with norgestomet implants. Reducing the duration of norgestomet treatment to 11 days and administration of PGF2 alpha at the time of ending treatment with a CIDR device resulted in no differences in fertility, mean intervals to oestrus or synchrony of oestrus.

Comparison of three methods of acute administration of progesterone on ovarian follicular development and the timing and synchrony of ovulation in Bos indicus heifers

The aim of this study was to induce the formation of a persistent dominant ovarian follicle and to compare the effects of 3 methods of acute administration of P4 on ovarian follicular development and on the timing and synchrony of ovulation. Stage of the estrous cycle was initially synchronized in Bos indicus heifers with a norgestomet implants (3 mg) for 10 d and with an analogue of PGF2 alpha (15 mg) on the first and last day of norgestomet treatment. Eight days after removal of the implants, heifers were randomly assigned to 4 groups. All heifers received a norgestomet implant (Day 0), which was removed 17 d later (Day 17); PGF2 alpha was administered on Days 0 and 4. Heifers in the control group (n = 5) received no other treatment. On Day 10 heifers in Group P4C (n = 5) were treated with a CIDR for 24 h; heifers in Group P4O (n = 5) were administered 100 mg i.m. of P4 in oil, while heifers in Group P4S (n = 5) were administered 100 mg i.m. of P4 in saline/alcohol. Data were analyzed using bootstrap estimates of location (mean) and spread (standard deviation; SD). Compared with the control heifers, day of emergence of the ovulatory follicle was delayed, and age and duration of dominance of the ovulatory follicle were reduced in the P4C and P4O heifers (P < 0.05) but not in the P4S heifers (P > 0.05). In all groups treated with P4 both the mean and variability (SD) in the timing of ovulation did not differ with that of the control group (P > 0.05) but there was less variability in the day of emergence, age, duration of dominance and diameter of the ovulatory follicle than in the control group (P < 0.05). Delayed timing and reduced synchrony (SD) of ovulation and greater age of the ovulatory follicle (P < 0.05) occurred in P4S heifers than in P4C heifers. We conclude that administration of 100 mg of P4 in oil is as effective as treatment with a CIDR for synchronizing emergence and ovulation of a newly recruited dominant follicle. However, reduced synchrony of ovulation, greater age of the ovulatory follicle and delayed timing of ovulation occurred following administration 100 mg of P4 in saline/alcohol compared with the CIDR device.

Duration of ovulation suppression with subcutaneous silicone implants containing norgestomet in Bos indicus heifers and cows

The aim of this study is to determine the duration of suppressing oestrus or ovulation in Bos indicus heifers and cows using norgestomet (N) incorporated into a silicone implant. Twelve heifers and 18 cows undergoing oestrous cycles were allocated to one of two treatment groups (6 heifers and 9 cows per group). Animals were treated with a single subcutaneous (s.c.) silicone implant containing 3 mg of N or two identical silicone implants (6 mg of N in two silicone implants) on day 0 of the study. An analogue of prostaglandin F2-alpha was administered intramuscularly, to all animals on days 0 and 6 to induce regression of corpora lutea. Implants were removed from all animals on day 21. Animals were observed for signs of behavioural oestrus while implants were in situ and for 6 d following implant removal. Blood samples were collected on alternate days from day 0 to 20 and again on day 21 and analysed for plasma progesterone (P4). Transrectal ultrasonography was performed on days 0, 6, 10, 14, 18, 21, 24, 26,27, and along with concentration of P4 in plasma was used to confirm ovulation during the treatment period. The cumulative percentages of animals ovulating during the 21 days implants were in situ were 6.7% (3 mg of N in one silicone implant) and 0% (6 mg of N in two silicone implants)Intervals from implant removal to oestrus (mean +/- S.E.M.) did not differ significantly among animals treated with either 3 or 6 mg of N in silicone implants (46.8 +/- 7.0 vs. 55.4 +/- 7.1 h, P = 0.398). Variances in interval from implant removal to oestrus among animals treated with 3 or 6 mg of N in silicone implants were also homogeneous (P = 0.942). The mean diameter of the ovulatory follicle on day 21 was larger in the animals treated with 3 mg of N compared to animals treated with 6 mg of N in two silicone implants ( 13.1 +/- 0.8 vs. 9.7 +/- 0.7 mm, P = 0.005). We conclude that treatment with 3 mg of N in a silicone implant will suppress ovulation in Bos indicus heifers and most cows for 21 d. Six mg of N in two silicone implants will suppress ovulation for 21 d in both cows and heifers.

Effect of 48 h treatment with 17 beta-oestradiol or progesterone on follicular wave emergence and synchrony of ovulation in Bos indicus cows when administered at the end of a period of progesterone treatment

The objective of this study was to determine the effect of treatment with additional progesterone (P4) or 17 beta-oestradiol (E2) at the end of a period of P4 treatment on ovarian follicular development, ovulation time, and plasma gonadotrophin and steroid hormone concentrations of Bos indicus cows. Initially, two injections of PGF2 alpha were given 14 days apart, and at the time of the second injection (Day 0) all cows received a single P4-releasing controlled internal drug release (CIDR) device that was removed 10 days later. Control cows (Group 1, n = 8) received no other treatment. On Day 8, cows in Group 2 (n = 8) and Group 3 (n = 8) received either a s.c. implant containing E2, or a second CIDR device, respectively. All CIDR devices and E2 implants were removed at a similar time on Day 10. Treatment with E2 or P4 delayed mean (+/- SD) time of ovulation (113.1 +/- 25.6 h, 153.4 +/- 44.5 h and 150.8 +/- 25.1 h for Groups 1, 2 and 3, respectively; P < 0.05) and the mean time (+/- SD) of the luteinising hormone (LH) peak (87.4 +/- 24.5 h, 124.3 +/- 45.0 h and 122.3 +/- 25.04 h for Groups 1, 2 and 3, respectively; P < 0.05). Both treatments delayed the mean (+/- SD) day of emergence of the ovulatory follicle (7.7 +/- 3.6 days, 11.3 +/- 1.7 days and 11.1 +/- 1.5 days for Groups 1, 2 and 3, respectively; P < 0.05), and reduced the variability in the day of emergence of the ovulatory follicle (P < 0.05) compared with the control cows. Variability in age and duration of dominance of the ovulatory follicle was greater in control animals compared with treated animals (P < 0.05). Treatment with E2 on Days 9 and 10 did not alter mean concentrations of gonadotrophins in the cows in Group 2 compared with control cows (P > 0.05), whereas treatment of cows with an additional CIDR device resulted in greater mean concentrations of FSH and lesser concentrations of LH on Day 9 (P < 0.05) compared with cows in Groups 1 and 2. By Day 10 mean concentrations of gonadotrophins were similar among cows in all three groups. Concentrations of E2 were less in cows in Group 3 compared with cows in Groups 1 and 2 from Day 9 to Day 11 (P < 0.05). We conclude that treatment with either E2 or P4 can influence the pattern of ovarian follicular development and ovulation in cattle; however, the mechanism of action of the two treatments may differ. Atretogenic treatments for ovarian follicles applied at the end of a period of progesterone treatment did not improve synchrony of ovulation.

Synchronization of estrus and ovulation and associated endocrine changes in cows

The effects of 4 estrus synchronization treatments on intervals to and synchrony of estrus and ovulation, on timing of the preovulatory LH surge and associated changes in plasma progesterone, LH, FSH, and 17beta-estradiol (E(2)) were investigated in 48 Bos indicus cows. Treatment 1 consisted of 2 injections of PGF(2alpha) 14 d apart (n = 12); Treatment 2 of a subcutaneous 3-mg norgestomet implant and an intramuscular injection of 3 mg of norgestomet and 5 mg estradiol valerate, with the implant removed 10 d later (n = 12; norgestomet-estradiol); Treatment 3 of norgestomet-estradiol, with a subcutaneous injection of PMSG given at time of implant removal (Day 10; n = 12); and Treatment 4 of norgestomet implant (as for Treatments 2 and 3) inserted for 10 d, with an intramuscular injection of PGF(2alpha) given at the time of implant removal (n = 12). The experiment was conducted in 2 replicates (24 cows/replicate, 6 cows/group). Estrus, ovulation and timing of the preovulatory surge of LH varied less in cows treated with norgestomet-estradiol and PMSG than in cows in Treatments 1 and 4 (P < 0.008). Treatment with PMSG reduced variation in ovulation times and timing of the LH surge in cows treated with norgestomet-estradiol (P < 0.02). Concentrations of E(2) were higher in cows in Treatments 2 and 3 on the final day of treatment and at about 6 h post ovulation compared with cows in Treatments 1 and 4 (P < 0.05). Different methods for synchronizing estrus did not alter sequential endocrine and behavioral changes in relation to the timing of the LH peak, and the results were consistent with current recommendations for insemination times in Bos taurus cattle.

An evaluation of visual assessment for fertility in Brahman cross cows using the Bonsma technique

A technique of visual assessment of cattle for reproductive efficiency, described by Professor Jan Bonsma of South Africa, was evaluated in two well-managed large herds of 1/2 to 3/4 Brahman cross heifers and cows located in the dry tropics of north Australia. Individual lifetime performance records were available for all animals. Experienced cattlemen carried out the assessments. Higher scores were previously claimed to indicate higher fertility. The technique had high repeatability (0.7) and was quickly learned by the assessors. Scores from visual assessment had no useful predictive value for either heifer or cow fertility or for growth rate up to 27 mo of age, although 2.5-yr-old heifers which were scored as subfertile matured into 4% smaller cows than heifers which had scored higher. Scores decreased as fatness increased (P < 0.05). Some biases in visual assessment occurred. Lactating cows scored higher than nonlactating cows (P < 0.05), independently of their reproductive record. Red and grey cows scored higher than brindle and black/brown cows (P < 0.05). Bonsma scores were not influenced by the percentage of Brahman in the genotype. Significant, but apparently random, age effects on scores also occurred. It was concluded that the visual assessment criteria described by Bonsma were of no practical value in assessing potential productivity of breeding animals in well-managed Brahman cross cattle in the dry tropics.

A competitive enzyme immunoassay for the direct determination of mometasone furoate (SCH 32088) in human plasma

Mometasone furoate (SCH 32088) is a synthetic corticosteroid which has a topical anti-inflammatory activity with a minimal potential for suppressing hypothalamic-pituitary-adrenocortical (HPA) axis. A sensitive competitive enzyme immunoassay (EIA) for measuring SCH 32088 in unextracted human plasma has been developed. The 3-(O-carboxymethyl)oxime (CMO) of SCH 32088 was synthesized and conjugated with bovine thyroglobulin, and the product was used for the production of antibodies in rabbits. SCH 32088-3-CMO was also conjugated with horseradish peroxidase, which was used as the tracer. The EIA thus developed can detect 1 pg SCH 32088 per assay or 25 pg per ml of human plasma. It can reliably quantitate SCH 32088 in human plasma from 50 pg ml-1 to 2.5 ng ml-1 with good linearity, accuracy and precision. The assay can be extended to measure SCH 32088 in plasma of laboratory animals. The availability of this sensitive assay makes it possible to evaluate the pharmacokinetics and toxicokinetics of SCH 32088 in laboratory animals and man.

Patterns of development of gonads, sex-drive and hormonal responses in tropical beef bulls

The development of different traits was studied in tropical beef bulls of seven genotypes (Brahman, Africander, British and combinations of these) from approximately 500 to 910 d of age. Bulls were raised under pasture conditions without supplementation. At each examination, approximately 2 mo apart, bulls were weighed, palpated (including scrotal and testicular measurement), electroejaculated, and subjected to two libido tests with estrus-induced females. At alternate examinations, plasma luteinizing hormone (LH) was measured at 30 and 150 min post gonadotrophin releasing hormone (GnRH) injection (LH - 30 and LH - 150) and testosterone (T) was measured at 150 min (T - 150). In general, nutritional and environmental stressors appeared to impede bull reproductive development. Scrotal circumference increased nonlinearly, apparently influenced by puberty and average daily gain (ADG). Libido increased overall, albeit nonlinearly also. No apparent marked differences in development of either trait could be attributed to genotype differences, although Brahman bulls tended to display lower sexual interest. The LH-30 level was relatively high (>14 ng/ml) at 500 and 640 d of age, but then dropped markedly at 760 d followed by a slight recovery. The LH-150 level followed a similar pattern, although it was very low at 500 d of age. The T-150 level showed a reverse pattern, being lower initially and higher in the latter part of the study. No apparent genotype differences occurred. Possible contributory influences on these patterns, including the onset of puberty and sexual maturity, season and nutrition, are discussed herein.

Preparation of europium-labeled derivatives of cortisol for time-resolved fluoroimmunoassays

Cortisol 3-(O-carboxymethyl)oxime, 6- and 21-hemisuccinoxycortisol, and cortisol 7-carboxyethyl thio-ether were synthesized. These carboxyl derivatives were labeled using a described general labeling method with a europium chelate. The labeled steroids were tested in a competitive time-resolved fluoroimmunoassay using antibodies raised against cortisol. Only the site-homologous antigen-antibody pairs underwent immunoreaction and gave satisfactory calibration curves.

Enzyme immunosorbant assay of oestradiol in unextracted plasma using penicillinase as label

An enzyme-linked immunosorbant assay (ELISA) for measuring oestradiol directly in plasma without extraction utilizing antibodies raised against oestradiol-3-(O-carboxymethyl) ether-bovine serum albumin conjugate, and oestradiol-6-(O-carboxymethyl) oxime linked to penicillinase (EC 3.5.2.6) as a marker was developed. Polyvinyl 96-well microtitre plates were used for immobilization of anti-oestradiol IgG. Standards of oestradiol (92 to 9,190 pmol/l were prepared in oestradiol-free plasma and 8-anilino-1-naphthalene sulphonic acid (8-ANS, 5 mg/ml of 10 mmol/l PBS) was added to the microtitre plate wells to displace oestradiol from plasma binding proteins. The assay had a lower limit of detection of 92 pmol/l plasma and could be performed within 4 h. Comparison of oestradiol values of 51 plasma specimens obtained by ELISA with those of radioimmunoassay (RIA), in which oestradiol was extracted with diethyl ether, showed good correlation (y = 0.786x + 0.03; r = 0.900).

Bioluminescent enzyme immunoassay for progesterone using monoclonal antibodies and glucose-6-phosphate dehydrogenase labels

Bacterial luciferase, NAD(P): FMN oxidoreductase and anti-mouse immunoglobulin were co-immobilized on Sepharose 4B. This reagent together with a progesterone glucose-6-phosphate dehydrogenase conjugate and various anti-progesterone monoclonal antibodies was used to develop a non-separation bioluminescent immunoassay for progesterone. This monoclonal antibody based assay was sensitive and reliable and using the tracer progesterone-11-acetate-glucose-6-phosphate dehydrogenase, the majority of the monoclonal antibodies give a better sensitivity with this enzymatic tracer than that obtained with an iodinated tracer. In a second assay design progesterone-glutathione was co-immobilized with bacterial luciferase and NAD(P): FMN oxidoreductase on Sepharose 4B and three monoclonal antibodies were labelled with glucose-6-phosphate dehydrogenase. With aqueous progesterone standards, this assay gave comparable sensitivity to the bioluminescent enzyme immunoassay using the second antibody immunoadsorbent and to an RIA but was unsuitable for plasma samples.

Characterization of LH and testosterone responses to intramuscular injection of GnRH in tropical postpubertal bulls

Five Zebu x British crossbred bulls 17 months of age and of uniform liveweight (320+/-3 kg) were used to study testosterone responses to single intramuscular doses of exogenous gonadotropin-releasing hormone (GnRH). The eight dose levels used were 0, 31.25, 62.5, 125, 250, 500, 1000, and 2000 ng GnRH/kg live weight. Plasma samples for hormone responses were collected at 30-minute intervals from zero to three hours and at one-hour intervals from three to seven hours postinjection. Luteinizing hormone (LH) and testosterone responses were measured as peak heights or as areas under response curves. Increasing the dosage of GnRH increased the time to reach the peak LH response, the height and duration of the response, and the area under the response curve. The maximum LH peak height was reached by the 1 mug/kg dose. In contrast to LH, testosterone responses reached the same peak heights (two hours postinjection of GnRH) for all doses of GnRH. The only effect of increased dosage was to increase the duration of response. Testosterone responses showed repeatable differences (P<0.01) between animals, but LH responses did not. It was demonstrated that the testosterone status of bulls can be accurately assessed by simply measuring testosterone in a single plasma sample collected two to three hours after the intramuscular injection of 100 mug or more (dose unimportant) of GnRH per bull.

Reproductive performance and productive traits of beef bulls selected for different levels of testosterone response to GnRH

In two separate studies, one with four Hereford-Shorthorn and one with three Zebu x British crossbred bulls, the efficacy of using the testosterone response to gonadotrophin-releasing hormone (GnRH; Lutal, Hoechst) to predict differences in reproductive performance was assessed. Young bulls (17 or 29 months of age) selected for low to high (3.1 to 10.3 ng/ml) peak plasma testosterone 2 to 2.5 hours after the intramuscular injection of GnRH (62.5 to 2000 ng/kg LWT) were each later individually joined with groups of 19 to 30 cows in which estrus had been synchronized. In both studies, the rankings of bulls for overall fertility (capable cows pregnant), for libido (estrous cows mounted), and for fertilizing ability (mounted cows pregnant) were in close agreement with rankings for testosterone responses to GnRH. In the Bos indicus bulls rankings for both reproductive performance and testosterone response to GnRH were repeatable when measured at two and four years of age. Other reproductive measurements (semen quality, scrotal circumference, pen-type serving capacity tests) were less reliable predictors of reproductive performance. Measurements of liveweight gains and parasite resistance indicated that bulls superior for these characteristics do not always have satisfactory reproductive performance. These studies suggest that the testosterone response to GnRH could be a useful test to ensure that bulls selected for productive traits have adequate reproductive potential.

Lack of influence of testosterone on sebum output and composition in bovines

Experiments were conducted to determine if testosterone influences sebum output (SO) and composition (SC) in different genotypes of cattle. There were significant breed differences in plasma testosterone levels and SO but no relationship was established between the two variables. Castration of neonatal and adult bulls did not affect their subsequent SO or SC. Testosterone treatment of steers failed to change SO. There were no differences in SO or SC between bulls and heifers. The results showed that testosterone does not influence sebum production in bovines and that there was a strong genetic control over SO independent of sex.

Serum progesterone concentration during the luteal phase in women with benign breast disease

Earlier studies of the serum concentration of progesterone during the luteal phase in women with benign breast disease have produced conflicting results. Serum progesterone profiles were therefore measured in relation to cyclical breast pain and in biopsied benign disease. No evidence of progesterone deficiency was found.

Patterns of puberal development in Sahiwal and Brahman cross bulls in tropical Australia

Plasma LH and testosterone (T) concentrations were measured before (basal) and two hours after (peak) GnRH stimulation in 52 Bos indicus strain bulls between one and two years of age. The animals comprised 13 1 2 Brahman, 20 3 4 Brahman, 8 1 2 Sahiwal and 11 3 4 Sahiwal cross bulls and samples were collected at approximately seven week intervals. Basal- and peak-T concentrations increased between one and two years of age, and basal LH concentrations decreased; no changes in peak LH were noted over time. Peak-T concentrations were significantly correlated with scrotal circumference (SC), sperm per ejaculate and seminal fructose. Significant genotype differences were noted, Sahiwal cross bulls had higher peak-T concentrations at puberty than Brahman cross bulls.

Danazol binding to steroid receptors in human uterine endometrium

To understand the mechanism of action of danazol, the binding of danazol to multiple classes of intracellular steroid binding proteins was studied in the human uterine endometrium. Danazol bound to endometrial receptors for estrogen, progesterone, and androgen and seemed to bind to endometrial intracellular corticosteroid-binding globulin and sex-hormone-binding globulin. Danazol occupies almost all binding sites of steroids in the steroid target cells in spite of the presence of endogenous steroids. It is speculated that the binding behavior of danazol may be related to its therapeutic effect on endometriosis.

Serum hormone and steroid hormone receptor levels during luteal-phase and long-term treatment with danazol

This study was designed to clarify the effects of danazol on levels of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, progesterone (P), and 17 beta-estradiol and endometrial steroid receptors (for estrogen [ER], progestin [PR], and androgen [AR] ) during luteal-phase and long-term treatment. These levels were compared with midluteal-phase levels for a histologically in-phase endometrium. Danazol given during the luteal phase to patients with in-phase endometrium decreased endometrial steroid receptor levels (total ER and total PR), and decreased serum P, LH, and FSH levels. Ten of the 17 patients treated (59%) still had in-phase endometrium. Danazol (400 mg/day) given for 1 month or more to patients with pelvic endometriosis increased serum LH and FSH levels within the normal range and endometrial total ER and PR levels. It appears that the effects of short-term and long-term treatment with danazol on serum hormone and endometrial steroid receptor levels differ.

Effects of danazol on pulsatile gonadotropin patterns and on serum estradiol levels in normally cycling women

The effect of danazol on pulsatile luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol (E2) secretion was examined in eight premenopausal women by serial blood sampling on day 10 of the control and first treatment cycles and during 2 subsequent months of treatment. The mean frequency of LH pulses decreased, while the mean pulse amplitude and increment increased (P less than 0.05). The mean LH concentrations were significantly suppressed in four of eight subjects. The mean frequency of E2 pulses, mean increment, and mean integrated area were decreased (P less than 0.05). The mean integrated FSH area did not change significantly during treatment, and we were not able to demonstrate unequivocal FSH pulses. We conclude that danazol in premenopausal women (1) lowers serum E2 concentrations by decreasing the frequency and increment of E2 pulses, (2) prevents compensatory gonadotropin rise, and (3) lowers the frequency but increases the amplitude and increment of LH pulses. The latter change reflects probably divergent effects of the drug on the pituitary and hypothalamus and results in an inconsistent lowering of basal LH levels.

Evaluation of four methods for the direct assay of progesterone in unextracted serum

The analytical performance of four radioimmunoassays for the determination of progesterone in unextracted serum is evaluated. The methods include kits from Radioassay Systems Laboratories (RSL), Nordiclab, Behringwerke, and an in-house assay. Extraction of progesterone from serum is avoided in these methods by employing various agents to displace progesterone from binding proteins. The radioimmunoassays employ125I-labelled progesterone derivatives, and bound and free fractions are separated by double antibody, polyethylene glycol or charcoal methods. The in-house method gives essentially quantitative recovery of progesterone, and results of patients' specimens correlate well with those obtained by a reference method involving extraction of serum. The Nordiclab kit gives progressive under-recovery of progesterone with increasing progesterone concentration, and results of patients' specimens correlate poorly with those obtained by other methods. Gross over-recovery of progesterone is obtained with the RSL kit, and results of patients' specimens are approximately three-fold higher than those of the reference method. The Behringwerke kit is precise but biased, progesterone levels being over-estimated in both recovery pools and patients' specimens. The performance of these methods and their suitability for the assessment of luteal function are discussed.

Danazol: endocrine pharmacology and therapeutic applications

The options for the medical management of endometriosis have been expanded by the introduction of the synthetic steroid, danazol. The results of large clinical studies suggest that danazol treatment produces significant improvement in the symptoms, signs, and laparoscopic findings of endometriosis. The original studies of the pharmacology of danazol concluded that danazol was a strong antigonadotrophin with mild androgenic effects and no other hormonal properties. Recent studies which emphasize the molecular pharmacology of danazol suggest that this steroid has direct effects on hypothalamic-pituitary function, multiple classes of steroid receptors, gonadal steroidogenesis, and endogenous steroid metabolism. These studies demonstrate that: (1) danazol prevents the midcycle surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH); (2) danazol does not significantly suppress basal LH or FSH in gonadally intact human beings; (3) in castrated animals danazol can prevent the compensatory increase in LH and FSH; (4) danazol binds to androgen, progesterone, and glucocorticoid receptors; (5) danazol does not bind to estrogen receptors; (6) danazol binds to sex hormone-binding globulin and corticosteroid-binding globulin; (7) danazol inhibits multiple enzymes of steroidogenesis; (8) danazol increases the metabolic clearance rate of progesterone; and (9) metabolites of danazol are hormonally active. Given the complex pharmacology of danazol it is inappropriate to continue to refer to danazol as a "selective antigonadotrophin."U

Radioimmunoassay of estradiol-17 beta in unextracted ewe plasma

A radioimmunoassay for estradiol-17 beta (E 2 beta) without solvent extraction is described. It can be used for plasma samples with concentrations higher than 10 pg/ml. Tritiated E 2 beta, and a specific antiserum in phosphate buffer were added to plasma samples, the total incubation volume being 0,5 ml. An identical volume of steroid free plasma to that assayed in unknowns (0.050 -0.2 ml) was added to the standard curve. Immunoprecipitation was used to separate bound and free E2 beta and the bound radioactivity counted in the polyproplene assay tube. The calculated regression of E2 beta measured on plasma loaded with excess E2 beta (y = 0.987x / 3.8; R = 0.99) and that of E2 beta measured in the same sample by the direct assay on that of E2 beta found by a reference extraction method (y = 0.998x / 14.9; R = 0.98) as well as the presence of parallelism between the standard curve and different volumes of plasma and acceptable inter and intra assay coefficients of variation show that this method is suitable for the measurement of E2 beta in uteroovarian venous plasma. However, this method cannot be used for peripheral plasma of pregnant animals because it is not specific. The method was found useful in a study on the effect of gonadotrophin pulses on the ovary when many samples had to be analysed. Furthermore, there is a potential for automatization which would facilitate more detailed analyses of ovarian-hypophyseal relationships.

Testosterone radioimmunoassay: rapid extraction technique for steroids based on kieselguhr mini-columns

A technique for the rapid extraction of steroids from serum prior to their radioimmunoassay is described. The technique is based on the use of mini-columns filled with kieselguhr (Extrelut; Merck). The columns provide a means of achieving a rapid and precise extraction without the problem of emulsion formation and without the necessity to accurately measure organic solvent volumes. The technique is inexpensive, time saving and at least as precise as most conventionally extracted steroid assays. The results achieved correlate well with those of a conventionally extracted assay.